Company intelligence / Profile preview

Delta Opportunity Fund

New York, New York, USA

Ownership: Private
Development stage: Other

Overview

Delta Opportunity Fund was a healthcare-focused investment fund managed by Diaz & Altschul Capital Management. The fund specialized in venture and growth-stage investments within the life sciences sector, targeting both privately-held and publicly-traded biotechnology and pharmaceutical companies. Notable investments included SUGEN, Cephalon, Corcept Therapeutics, and Esperion Therapeutics. The fund was led by managing members such as Patrick Enright and Reinaldo Diaz before its principals transitioned to other firms like Longitude Capital and Opna Bio.

Industry: Investors

Beyond the preview

Go deeper on Delta Opportunity Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta Opportunity Fund.

Explore the full profile